{"type":"article","show_header_text":true,"header":"ARTICLES ABOUT DANIEL VASELLA","query":"(per=\"VASELLA, DANIEL\") and tom!=\"Caption\" and tom!=\"Correction\" and tom!=\"List\" and tom!=\"Paid Death Notice\" and dsk!=\"Society\"","search_query":"(persons:\"VASELLA, DANIEL\") AND -type_of_material:\"Caption\" AND -type_of_material:\"Correction\" AND -type_of_material:\"List\" AND -type_of_material:\"Paid Death Notice\" AND -news_desk:\"Society\"","num_search_articles":"10","show_summary":true,"show_byline":true,"show_pub_date":true,"hide_thumbnails":false,"show_kicker":false,"show_title":false,"show_related_topics":true,"show_rad_links":true,"show_subtopics":true,"exclude_topics":"VASELLA, DANIEL","more_on_header":"MORE ON DANIEL VASELLA AND:","alternate_index_subidx":"","show_thumbnails":true}

After weeks of speculation in the drug industry on whether Novartis would seek to counter Sanofi-Synthélabo's unsolicited offer for Aventis, the company said yesterday that it would stay out of the bidding unless French officials stopped promoting...

Novartis, Switzerland's leading drug company, reported a 15 percent rise in fourth-quarter profits Thursday, better than expected, and also revealed that it had increased its stake in Roche Holding by a hairbreadth to the crucial one-third threshold....

Novartis, the Swiss drug giant, said at an investor conference yesterday that it intends to rely increasingly on advertising to consumers to wring more sales out of its current crop of big sellers. The company also said that its pipeline was...

THIS quaint city on the Rhine once boasted three of the world's biggest drug companies. If Daniel L. Vasella has his way, there could be just one. Dr. Vasella, who practiced medicine here before becoming a drug industry executive and chairman of...

Novartis said today that it had accumulated enough stock in the Roche Group, one of its main rivals, to control 32.7 percent of the voting rights in the company. The announcement, made at a briefing for analysts and reporters in this Zurich...

Novartis said that sales over the last nine months rose 11 percent, better than expected, as it benefited from two popular heart medications. The chairman of Novartis, Daniel Vasella, said that the company was on track for double-digit growth this...

October 12, 2001, Friday

When the announcement came last month that Novartis would sell its agricultural division, few analysts were surprised. But it had to be a bittersweet moment for Daniel Vasella, the chairman of Novartis. Just three and a half years earlier, Dr....